Healthcare / BiotechnologyNasdaqGM
$7.19
-0.10 (-1.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-42.4M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$444M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.8%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-51.0M · FCF $-45.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $2.0M | — |
| Net Income | $-51.0M | $-51.0M | $-45.6M | $-27.9M | $-30.5M |
| EBITDA | $-56.9M | $-56.9M | $-54.5M | $-30.7M | $-31.1M |
| EPS | — | — | -1.45 | -2.66 | -1.38 |
| Operating Margin | — | — | — | -1537.0% | — |
| Net Margin | — | — | — | -1393.8% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Current Ratio | 20.34 | 20.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-45.6M | $-45.6M | $-42.4M | $-23.8M | $-24.5M |
| Returns | |||||
| ROE | -45.8% | -45.8% | -29.2% | -30.6% | 16.3% |
| Valuation | |||||
| P/B | 2.10 | 2.10 | 1.00 | 0.55 | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 45.5% | -93.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+102.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.45 → n/d
Residual
+102.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.